Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian Countries

Tomasz Bochenek*, Vafa Abilova, Ali Alkan, Bogdan Asanin, Iñigo de Miguel Beriain, Zeljka Besovic, Patricia Vella Bonanno, Anna Bucsics, Michal Davidescu, Elfi De Weerdt, Natasa Duborija-Kovacevic, Jurij Fürst, Mina Gaga, Elma Gailite, Jolanta Gulbinovič, Emre U. Gürpinar, Balázs Hankó, Vincent Hargaden, Tor A. Hotvedt, Iris HoxhaIsabelle Huys, Andras Inotai, Arianit Jakupi, Helena Jenzer, Roberta Joppi, Ott Laius, Marie Camille Lenormand, Despina Makridaki, Admir Malaj, Kertu Margus, Vanda Marković-Peković, Nenad Miljković, João L. de Miranda, Stanislav Primožič, Dragana Rajinac, David G. Schwartz, Robin Šebesta, Steven Simoens, Juraj Slaby, Ljiljana Sović-Brkičić, Tomas Tesar, Leonidas Tzimis, Ewa Warmińska, Brian Godman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)

Abstract

Drug shortages have been identified as a public health problem in an increasing number of countries. This can negatively impact on the quality and efficiency of patient care, as well as contribute to increases in the cost of treatment and the workload of health care providers. Shortages also raise ethical and political issues. The scientific evidence on drug shortages is still scarce, but many lessons can be drawn from cross-country analyses. The objective of this study was to characterize, compare, and evaluate the current systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages within health care systems across a range of European and Western Asian countries. The study design was retrospective, cross-sectional, descriptive, and observational. Information was gathered through a survey distributed among senior personnel from ministries of health, state medicines agencies, local health authorities, other health or pharmaceutical pricing and reimbursement authorities, health insurance companies and academic institutions, with knowledge of the pharmaceutical markets in the 28 countries studied. Our study found that formal definitions of drug shortages currently exist in only a few countries. The characteristics of drug shortages, including their assortment, duration, frequency, and dynamics, were found to be variable and sometimes difficult to assess. Numerous information hubs were identified. Providing public access to information on drug shortages to the maximum possible extent is a prerequisite for performing more advanced studies on the problem and identifying solutions. Imposing public service obligations, providing the formal possibility to prescribe unlicensed medicines, and temporary bans on parallel exports are widespread measures. A positive finding of our study was the identification of numerous bottom-up initiatives and organizational frameworks aimed at preventing or mitigating drug shortages. The experiences and lessons drawn from these initiatives should be carefully evaluated, monitored, and presented to a wider international audience for careful appraisal. To be able to find solutions to the problem of drug shortages, there is an urgent need to develop a set of agreed definitions for drug shortages, as well as methodologies for their evaluation and monitoring. This is being progressed.

Original languageEnglish
Article number942
JournalFrontiers in Pharmacology
Volume8
Issue numberJAN
DOIs
Publication statusPublished - 18 Jan 2018
Externally publishedYes

Keywords

  • Drug shortage
  • Europe
  • European Union
  • Health care system
  • Legislation
  • Organizational framework
  • Pharmaceutical policy
  • Western Asia

Fingerprint

Dive into the research topics of 'Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian Countries'. Together they form a unique fingerprint.

Cite this